Last reviewed · How we verify

Aclacinomycin, Cytarabine — Competitive Intelligence Brief

Aclacinomycin, Cytarabine (Aclacinomycin, Cytarabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (anthracycline + nucleoside analog). Area: Oncology.

marketed Chemotherapy combination (anthracycline + nucleoside analog) DNA (topoisomerase II for aclacinomycin; DNA polymerase for cytarabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aclacinomycin, Cytarabine (Aclacinomycin, Cytarabine) — The First Hospital of Jilin University. This combination of aclacinomycin and cytarabine works by intercalating into DNA and inhibiting DNA synthesis to kill rapidly dividing cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aclacinomycin, Cytarabine TARGET Aclacinomycin, Cytarabine The First Hospital of Jilin University marketed Chemotherapy combination (anthracycline + nucleoside analog) DNA (topoisomerase II for aclacinomycin; DNA polymerase for cytarabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (anthracycline + nucleoside analog) class)

  1. The First Hospital of Jilin University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aclacinomycin, Cytarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/aclacinomycin-cytarabine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: